Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-2910-02 Phase IIa Trial in Diabetic Polyneuropathy
jRCT2061210008Phase 2Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic polyneuropathy (DPN) comparing ONO-2910 300 mg once daily with Placebo once daily (2 arms). Primary endpoints: Change from baseline at week 12 in total mTCNS numbness and tingling score, Safety assessments and 1 more. Started Jun 2021; status: completed.
02
Drugs
ONO-2910
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on jRCT2061210008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061210008.